title: C-Abl as a modulator of p53.
abstract: P53 is renowned as a cellular tumor suppressor poised to instigate remedial responses to various stress insults that threaten DNA integrity. P53 levels and activities are kept under tight regulation involving a complex network of activators and inhibitors, which determine the type and extent of p53 growth inhibitory signaling. Within this complexity, the p53-Mdm2 negative auto-regulatory loop serves as a major route through which intra- and extra-cellular stress signals are channeled to appropriate p53 responses. Mdm2 inhibits p53 transcriptional activities and through its E3 ligase activity promotes p53 proteasomal degradation either within the nucleus or following nuclear export. Upon exposure to stress signals these actions of Mdm2 have to be moderated, or even interrupted, in order to allow sufficient p53 to accumulate in an active form. Multiple mechanisms involving a variety of factors have been demonstrated to mediate this interruption. C-Abl is a critical factor that under physiological conditions is required for the maximal and efficient accumulation of active p53 in response to DNA damage. C-Abl protects p53 by antagonizing the inhibitory effect of Mdm2, an action that requires a direct interplay between c-Abl and Mdm2. In addition, c-Abl protects p53 from other inhibitors of p53, such as the HPV-E6/E6AP complex, that inhibits and degrades p53 in HPV-infected cells. Surprisingly, the oncogenic form of c-Abl, the Bcr-Abl fusion protein in CML cells, also promotes the accumulation of wt p53. However, in contrast to the activation of p53 by c-Abl, its oncogenic form, Bcr-Abl, counteracts the growth inhibitory activities of p53 by modulating the p53-Mdm2 loop. Thus, it appears that by modulating the p53-Mdm2 loop, c-Abl and its oncogenic forms critically determine the type and extent of the cellular response to DNA damage.
authors.affiliation: Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, Jerusalem 91120, Israel.
authors.forename: Yaara
authors.initials: Y
authors.lastname: Levav-Cohen
authors.forename: Zehavit
authors.initials: Z
authors.lastname: Goldberg
authors.forename: Valentina
authors.initials: V
authors.lastname: Zuckerman
authors.forename: Tamar
authors.initials: T
authors.lastname: Grossman
authors.forename: Sue
authors.initials: S
authors.lastname: Haupt
authors.forename: Ygal
authors.initials: Y
authors.lastname: Haupt
mesh_terms: D000818:Animals; D004249:DNA Damage; D016313:Genes, abl; D016158:Genes, p53 / Q000187:drug effects; D006801:Humans; D009687:Nuclear Proteins / Q000187:drug effects / Q000502:physiology; D015514:Oncogene Proteins, Fusion / Q000502:physiology; D009856:Oncogene Proteins, Viral / Q000037:antagonists & inhibitors; D011499:Protein Processing, Post-Translational; D011518:Proto-Oncogene Proteins / Q000187:drug effects / Q000502:physiology; D016315:Proto-Oncogene Proteins c-abl / Q000502:physiology*; D051736:Proto-Oncogene Proteins c-mdm2; D016159:Tumor Suppressor Protein p53 / Q000502:physiology*
chemical_list: C466080:E6 protein, human papillomavirus type 1; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D009856:Oncogene Proteins, Viral; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D016315:Proto-Oncogene Proteins c-abl